Income Statement Hansoh Pharmaceutical Group Company Limited
Stocks
3692
KYG549581067
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.30 HKD | +2.59% |
|
-5.54% | -18.79% |
| 02:12pm | Hansoh Pharmaceutical's Application for HS-10568 Injection Accepted in China | MT |
| 06-09 | Weight-loss drug developers line up to tap lucrative market as competition heats up | RE |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 9.94B | 9.38B | 10.1B | 12.26B | 15.03B | |||||
Total Revenues | 9.94B | 9.38B | 10.1B | 12.26B | 15.03B | |||||
Cost of Goods Sold, Total | 870M | 870M | 1.03B | 1.12B | 1.52B | |||||
Gross Profit | 9.06B | 8.51B | 9.07B | 11.14B | 13.51B | |||||
Selling General & Admin Expenses, Total | 4.37B | 4.15B | 4.24B | 4.51B | 4.74B | |||||
R&D Expenses | 1.8B | 1.69B | 2.1B | 2.7B | 3.36B | |||||
Other Operating Expenses | - | 63.73M | 53.9M | 31.98M | 14.3M | |||||
Other Operating Expenses, Total | 6.17B | 5.9B | 6.39B | 7.24B | 8.11B | |||||
Operating Income | 2.9B | 2.61B | 2.68B | 3.9B | 5.4B | |||||
Interest Expense, Total | -52.82M | -58.14M | -66.68M | -6.69M | -3.16M | |||||
Interest And Investment Income | 254M | 332M | 1.02B | 1.05B | 1.1B | |||||
Net Interest Expenses | 201M | 273M | 953M | 1.04B | 1.09B | |||||
Income (Loss) On Equity Invest. | - | -13.86M | -2.12M | - | - | |||||
Currency Exchange Gains (Loss) | -9.31M | 44.56M | 4.57M | 21.43M | -44.06M | |||||
Other Non Operating Income (Expenses) | 63.43M | 117M | 105M | 87.35M | 111M | |||||
EBT, Excl. Unusual Items | 3.15B | 3.03B | 3.74B | 5.05B | 6.56B | |||||
Gain (Loss) On Sale Of Investments | 144M | -91.54M | 158M | 61.27M | -16.71M | |||||
Gain (Loss) On Sale Of Assets | 3.94M | 11.24M | 2.1M | 5.72M | 4.3M | |||||
Asset Writedown | - | - | - | -31.98M | - | |||||
Other Unusual Items | - | - | -135M | - | - | |||||
EBT, Incl. Unusual Items | 3.3B | 2.95B | 3.77B | 5.09B | 6.55B | |||||
Income Tax Expense | 587M | 365M | 489M | 713M | 995M | |||||
Earnings From Continuing Operations | 2.71B | 2.58B | 3.28B | 4.37B | 5.56B | |||||
Net Income to Company | 2.71B | 2.58B | 3.28B | 4.37B | 5.56B | |||||
Net Income - (IS) | 2.71B | 2.58B | 3.28B | 4.37B | 5.56B | |||||
Net Income to Common Incl Extra Items | 2.71B | 2.58B | 3.28B | 4.37B | 5.56B | |||||
Net Income to Common Excl. Extra Items | 2.71B | 2.58B | 3.28B | 4.37B | 5.56B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 0.46 | 0.44 | 0.55 | 0.74 | 0.93 | |||||
Basic EPS - Continuing Operations | 0.46 | 0.44 | 0.55 | 0.74 | 0.93 | |||||
Basic Weighted Average Shares Outstanding | 5.92B | 5.92B | 5.92B | 5.93B | 5.96B | |||||
Net EPS - Diluted | 0.44 | 0.44 | 0.52 | 0.73 | 0.93 | |||||
Diluted EPS - Continuing Operations | 0.44 | 0.44 | 0.52 | 0.73 | 0.93 | |||||
Diluted Weighted Average Shares Outstanding | 6B | 5.93B | 6.02B | 5.95B | 5.98B | |||||
Normalized Basic EPS | 0.33 | 0.32 | 0.39 | 0.53 | 0.69 | |||||
Normalized Diluted EPS | 0.33 | 0.32 | 0.39 | 0.53 | 0.69 | |||||
Dividend Per Share | 0.07 | 0.09 | 0.19 | 0.32 | 0.39 | |||||
Payout Ratio | 14.04 | 27.56 | 19.9 | 42.51 | 36.22 | |||||
American Depositary Receipts Ratio (ADR) | 5 | 5 | 5 | 5 | 5 | |||||
Supplemental Items | ||||||||||
EBITDA | 3.15B | 2.93B | 3.02B | 4.28B | 5.76B | |||||
EBITA | 2.9B | 2.62B | 2.69B | 3.92B | 5.41B | |||||
EBIT | 2.9B | 2.61B | 2.68B | 3.9B | 5.4B | |||||
EBITDAR | 3.18B | 2.94B | 3.03B | 4.28B | 5.77B | |||||
Effective Tax Rate - (Ratio) | 17.79 | 12.37 | 12.97 | 14.03 | 15.19 | |||||
Total Current Taxes | 442M | 281M | 584M | 768M | 1.12B | |||||
Total Deferred Taxes | 145M | 83.91M | -95.64M | -54.83M | -128M | |||||
Normalized Net Income | 1.97B | 1.89B | 2.34B | 3.16B | 4.1B | |||||
Interest on Long-Term Debt | 3.26M | 58.14M | 60.91M | 3.48M | 3.16M | |||||
Supplemental Operating Expense Items | ||||||||||
Marketing Expenses | - | - | - | - | - | |||||
Selling and Marketing Expenses | 3.43B | 3.55B | 3.53B | 3.8B | 4.06B | |||||
General and Administrative Expenses | 943M | 597M | 710M | 713M | 672M | |||||
Research And Development Expense From Footnotes | 1.8B | 1.69B | 2.1B | 2.7B | 3.36B | |||||
Net Rental Expense, Total | 29.42M | 8.65M | 5.46M | 4.51M | 4.68M | |||||
Imputed Operating Lease Interest Expense | 6.34M | 981K | 671K | 109K | 1.06M | |||||
Imputed Operating Lease Depreciation | 23.08M | 7.67M | 4.79M | 4.4M | 3.62M | |||||
Stock-Based Comp., Other (Total) | 65.47M | 179M | 171M | 138M | 143M | |||||
Total Stock-Based Compensation | 65.47M | 179M | 171M | 138M | 143M |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















